Fundamentals in Focus for Abeona Therapeutics Inc. (ABEO)

Abeona Therapeutics Inc. (NASDAQ:ABEO) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market value of 583.40M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For ABEO, the company currently has 58.3 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 96.66 million in total assets, balanced by 7.58 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Abeona Therapeutics Inc. (ABEO) saw -4.99 million in free cash flow last quarter, representing a quarterly net change in cash of -4.91 million. Perhaps most importantly where cash movements are concerned, the company saw about -4.98 million in net operating cash flow.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 217,000 in total revenues. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the ABEO saw sales decline by 0.00.

But what about the bottom line? After all, that’s what really matters in the end. Abeona Therapeutics Inc. (ABEO) is intriguing when broken down to its core data.  For shareholders, given the total diluted outstanding shares of 40.27 million, this means overall earnings per share of -0.21. Note, this compares with a consensus analyst forecast of -0.16 in earnings per share for its next fiscal quarterly report.

Is Abeona Therapeutics Inc. (NASDAQ:ABEO) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.73 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Abeona Therapeutics Inc..

Previous ArticleNext Article

Related Post

United Continental Holdings, Inc. (UAL) and KKR &#... United Continental Holdings, Inc. (NYSE:UAL) shares are up more than 0.68% this year and recently decreased -2.02% or -$1.4 to settle at $67.86. KKR &...
Financial Metrics You Should Care About: Netflix, ... The shares of Netflix, Inc. have increased by more than 70.75% this year alone. The shares recently went down by -1.48% or -$4.93 and now trades at $3...
A Side-by-side Analysis of International Paper Com... International Paper Company (NYSE:IP) shares are down more than -5.51% this year and recently decreased -0.45% or -$0.25 to settle at $54.75. The Blac...
Should You Buy Prudential Financial, Inc. (PRU) or... Prudential Financial, Inc. (NYSE:PRU) shares are down more than -8.63% this year and recently decreased -3.51% or -$3.82 to settle at $105.06. Clean E...
First Data Corporation (FDC) Sentiment Based on th... First Data Corporation (NYSE:FDC) gained 1.13% in yesterday’s session, going up from its prior closing price of $17.74 to $17.94. The price has fallen...